RECURRENT MYELODYSPLASTIC SYNDROME/ACUTE MYELOID LEUKEMIA
Clinical trials for RECURRENT MYELODYSPLASTIC SYNDROME/ACUTE MYELOID LEUKEMIA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT MYELODYSPLASTIC SYNDROME/ACUTE MYELOID LEUKEMIA trials appear
Sign up with your email to follow new studies for RECURRENT MYELODYSPLASTIC SYNDROME/ACUTE MYELOID LEUKEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Experimental drug TAK-243 targets tough blood cancers in early trial
Disease control Recruiting nowThis early-phase study is testing a drug called TAK-243 in people whose acute myeloid leukemia or myelodysplastic syndrome has come back or is not responding to treatment. The goal is to find the best dose and check for side effects. The trial is currently on hold.
Matched conditions: RECURRENT MYELODYSPLASTIC SYNDROME/ACUTE MYELOID LEUKEMIA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 29, 2026 00:00 UTC
-
New drug combo targets tough blood cancers in early trial
Disease control Recruiting nowThis early-stage trial is testing a new drug called cirtuvivint, alone or with another drug combo (ASTX727), in people with myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML). The goal is to find the safest dose and check for side effects. About 54 participants whose…
Matched conditions: RECURRENT MYELODYSPLASTIC SYNDROME/ACUTE MYELOID LEUKEMIA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC